XNAS
RVMDW
Market cap6.43bUSD
Apr 02, Last price
0.05USD
1D
51.14%
1Q
-62.21%
IPO
-94.71%
Name
Revolution Medicines Inc
Chart & Performance
Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | ||||||||
Revenues | 11,580 -67.27% | 35,380 20.38% | ||||||
Cost of revenue | 689,524 | 498,765 | 303,315 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (689,524) | (487,185) | (267,935) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 753 | (3,524) | (420) | |||||
Tax Rate | ||||||||
NOPAT | (690,277) | (483,661) | (267,515) | |||||
Net income | (600,093) 37.52% | (436,367) 75.46% | (248,705) 38.35% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 851,377 | 389,076 | 299,909 | |||||
BB yield | -11.60% | -11.99% | -15.62% | |||||
Debt | ||||||||
Debt current | 12,872 | 14,738 | 6,773 | |||||
Long-term debt | 258,814 | 168,519 | 121,637 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 3,859 | 7,970 | 301 | |||||
Net debt | (2,017,613) | (1,669,698) | (518,270) | |||||
Cash flow | ||||||||
Cash from operating activities | (557,436) | (350,572) | (224,401) | |||||
CAPEX | (10,308) | (7,729) | (10,816) | |||||
Cash from investing activities | (554,394) | (342,598) | (24,116) | |||||
Cash from financing activities | 959,413 | 1,229,200 | 301,432 | |||||
FCF | (732,086) | (509,939) | (270,015) | |||||
Balance | ||||||||
Cash | 2,289,299 | 1,852,955 | 644,943 | |||||
Long term investments | 1,737 | |||||||
Excess cash | 2,289,299 | 1,852,376 | 644,911 | |||||
Stockholders' equity | (1,736,462) | (1,137,148) | (703,112) | |||||
Invested Capital | 4,141,368 | 3,066,625 | 1,452,806 | |||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 167,738 | 113,150 | 80,627 | |||||
Price | 43.74 52.51% | 28.68 20.40% | 23.82 -5.36% | |||||
Market cap | 7,336,846 126.09% | 3,245,138 68.97% | 1,920,524 4.80% | |||||
EV | 5,319,233 | 1,575,440 | 1,402,254 | |||||
EBITDA | (733,020) | (477,876) | (258,279) | |||||
EV/EBITDA | ||||||||
Interest | 303 | 9,656 | ||||||
Interest/NOPBT |